AAPG Stock Forecast & Price Target

Ascentage Pharma Group has demonstrated strong commercial momentum, with sales of Olverembatinib reaching approximately RMB 217.4 million (around US$30.3 million) in the first half of 2025, marking a significant year-over-year increase of approximately 93%. The company's expanding field footprint now covers about 867 hospitals and includes a robust network of distributors and direct-to-patient pharmacies, indicating enhanced market penetration and accessibility. Additionally, the positive trend in capital formation within the Chinese biotech sector, alongside the substantial gains seen in related ETFs, suggests a favorable environment for continued growth and investment in Ascentage Pharma's innovative therapies.

Ascentage Pharma Group faces downward pressure on margins and revenue growth due to aggressive pricing strategies like the National Reimbursement Drug List (NRDL) repricing cycles and a challenging volume-based procurement program. The company's critical medication, venetoclax plus azacitidine, has shown declining complete response rates and failed to meet primary endpoints in pivotal studies, which could hinder its global expansion potential. Additionally, slower market adoption in China, coupled with potential intellectual property risks and a lack of competitive differentiation in global studies, raises concerns about the company’s ability to sustain its market position and achieve significant revenue growth.